Nova Mentis

Nova Mentis is the former name of a Canadian public life sciences company that operated as Nova Mentis Life Science Corp. before changing its name to Restart Life Sciences Corp. in November 2024. Under the Nova Mentis name, the company focused on psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory and neurodevelopmental disorders, with particular emphasis on fragile X syndrome and autism spectrum disorder. It also described Nova Mentis Biotech Corp. as an R&D-driven subsidiary exploring anti-inflammatory effects of psilocybin in metabolic indications such as obesity and diabetes. More recently, the parent company has shifted toward a broader health and wellness platform model under Restart Life, including functional foods and wellness brands. For biotech analysts, Nova Mentis is best understood as the legacy psychedelic-biotech identity of what is now Restart Life Sciences.